Search results for " CAR T cell therapy"
Article
Process Development: 2020 Reflections and 2021 Possibilities
The challenges posed by the COVID-19 pandemic in 2020 brought about many unprecedented lessons and promising developments in the biopharmaceutical industry. Last year in particular reenforced the ne…
Article
Improving Lentiviral Vector Downstream Processing Workflows
Lentiviral vectors (LVV) are a common vehicle to deliver genetic material in chimeric antigen receptor (CAR) T-cell therapy and gene therapy applications. Production methods have been developed by a…
Article
Process Development: What May Lie Ahead in 2018?
2018 is shaping up to be an interesting year in the world of biopharmaceuticals. What have 2017 developments taught us, and what may lie ahead for biopharmaceutical drug developers and process engin…
Article
Dear lentivirus: We have not forgotten about you and how to improve your polishing recovery
Lentiviruses are commonly used for both chimeric antigen receptor (CAR) T cell therapy and ex vivo gene therapy.
Vector purification is very challenging due to low stability of these envel…